

13464 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

to all drug products in this class. It is anticipated that the final labeling will conform with the guidelines for labeling of prescription drugs proposed by the Commissioner on April 7, 1975 (40 FR 15392).

I. GENERAL BACKGROUND

The following new drug applications have been approved for oral hypoglycemic drugs:

1. NDA 10,670, Orinase tablets containing tolbutamide; The Upjohn Co., 7000 Portage Rd., Kalamazoo, MI 49001.
2. NDA 15,500, Tolinase tablets containing tolazamide; The Upjohn Co.
3. NDA 11,641, Diabinese containing chlorpropamide; Pfizer Inc., 235 E. 42d St., New York, NY 10017.
4. NDA 13,378, Dymelor containing acetohexamide; Eli Lilly & Co., Indianapolis, IN 46206.
5. NDA 11,624, DBI tablets containing phenformin hydrochloride; Geigy Pharmaceuticals, Ardsley, NY 10502.
6. NDA 12,752, DBI-TD capsules containing phenformin hydrochloride; Geigy Pharmaceuticals.
7. NDA 17,126, Meltrol-50-100 capsules containing phenformin hydrochloride; USV Pharmaceutical Corp., 1 Scarsdale Rd., Tuckahoe, NY 10707.
8. NDA 17,127, Meltrol-25 tablets containing phenformin hydrochloride; USV Pharmaceutical Corp.
9. NDA 12,678, Tolbutamide tablets containing tolbutamide; Premo Pharmaceuticals Laboratories, Inc., 111 Leuning St., South Hackensack, NJ 07606.